ARCHIVES

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

U.S., France Offer Carcinogenesis Program

February 13, 1981

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

September 29, 2000

Preliminary estimates based on NLST results: Year Of Life Saved Could Cost $38,000

July 1, 2011

Advanced Screening Provides More Accurate Diagnosis

February 23, 2007

Funding Opportunities

December 6, 2002

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

April 27, 2012